9 completed, 3 terminated. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 6, Terminated 2 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow MEDI-507: new trials by email Literature Review of MEDI-507 trials Research Report on MEDI-507
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Renal Allograft Tolerance Through Mixed Chimerism MEDI-507, Rituximab, Total Body Irradiation - End Stage Renal Disease | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 2 | 2013-03-01 | 2021-04-19 |
| Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas Rituximab, Etoposide, Siplizumab - T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2009-01-13 | 2021-11-03 |
| Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection Kidney Transplantation, Bone marrow transplantation, MEDI-507 - Kidney Transplantation, Kidney Failure, Chronic | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 2008-12-01 | 2015-11-10 |
| Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia MEDI-507 - Lymphoma, Leukemia | Phase 1 | Terminated | MedImmune LLC | 80 | 2005-02-01 | 2007-06-14 |
| Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease MEDI-507 - Lymphoproliferative Disorders | Phase 1 | Terminated | MedImmune LLC | 31 | 2004-04-01 | 2007-06-14 |
| Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies MEDI-507, Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant - Lymphoma, Leukemia | Phase 2 | Terminated | Massachusetts General Hospital | 14 | 2002-11-01 | 2018-03-16 |
| A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis MEDI-507, Placebo - Plaque Psoriasis | Phase 2 | Completed | MedImmune LLC | 420 | 2001-09-01 | 2007-11-28 |
| Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis MEDI-507 - Psoriasis | Phase 2 | Completed | MedImmune LLC | 120 | 2001-03-01 | 2006-10-25 |
| Study of MEDI 507 in the Treatment of Pediatric Patients MEDI-507 - Graft Versus Host Disease | Phase 1 | Completed | MedImmune LLC | 10 | 1999-09-01 | 2008-12-23 |
| Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD) MEDI-507, Placebo - Graft-Versus-Host Disease | Phase 1 | Completed | MedImmune LLC | 34 | 1999-01-01 | 2008-12-11 |
| Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease MEDI-507 - Cancer, Graft-Versus-Host Disease | Phase 1 | Completed | MedImmune LLC | 17 | 1998-05-01 | 2008-12-11 |
| A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection MEDI-507 - Kidney Diseases | Phase 1 | Completed | MedImmune LLC | 13 | 1997-02-01 | 2008-12-12 |
Graft vs Host Disease (3) · Lymphoma (3) · Kidney Failure, Chronic (2) · Leukemia (2) · Neoplasms (2) · Kidney Diseases (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Lymphoproliferative Disorders (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Psoriasis (1) · Subcutaneous panniculitis-like T-cell lymphoma (1)
MedImmune LLC (8) · Massachusetts General Hospital (2) · National Cancer Institute (NCI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (12) · Canada (1)
J. Bruce McClain, M.D. (3) · A. Benedict Cosimi, M.D. (1) · Ben Cosimi, MD (1) · Christine A Dingivan, M.D. (1) · David Sachs, M.D. (1) · David Sachs, MD (1) · John Janik, MD (1) · Karen Kaucic, MD (1) · Luz Hammershaimb, MD (1) · Stanley Pillemer, MD (1) · Thomas Spitzer, M.D. (1) · Wyndham H Wilson, M.D. (1)